The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia

[1]  V. Schirrmacher,et al.  EGF receptor in neoplasia and metastasis , 1993, Cancer and Metastasis Reviews.

[2]  J. Giri,et al.  The enhanced in vitro hematopoietic activity of leridistim, a chimeric dual G-CSF and IL-3 receptor agonist , 2002, Leukemia.

[3]  P. Doshi,et al.  Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line , 2002, Leukemia.

[4]  T. Taira,et al.  MM-1, a c-Myc-binding Protein, Is a Candidate for a Tumor Suppressor in Leukemia/Lymphoma and Tongue Cancer* , 2001, The Journal of Biological Chemistry.

[5]  K. Moelling,et al.  Regulation of Raf by Akt Controls Growth and Differentiation in Vascular Smooth Muscle Cells* , 2001, The Journal of Biological Chemistry.

[6]  C. Osborne,et al.  Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. , 2001, Cancer research.

[7]  D. Giannella‐Neto,et al.  Interferon-alpha therapy increases type I insulin-like growth factor receptors expression on lymphoid cells from patients with chronic myelogenous leukemia. , 2001, Leukemia research.

[8]  J. McCubrey,et al.  Enhanced ability of daniplestim and myelopoietin-1 to suppress apoptosis in human hematopoietic cells , 2001, Leukemia.

[9]  J. McCubrey,et al.  P21Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells , 2001, Oncogene.

[10]  A. Adjei,et al.  Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.

[11]  E. Nishida,et al.  A Novel MAPK Phosphatase MKP-7 Acts Preferentially on JNK/SAPK and p38α and β MAPKs* , 2001, The Journal of Biological Chemistry.

[12]  J. Hancock,et al.  Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions , 2001, Oncogene.

[13]  J. Karp.  Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. , 2001, Seminars in hematology.

[14]  J. McCubrey,et al.  Suppression of apoptosis: role in cell growth and neoplasia , 2001, Leukemia.

[15]  P. Dent,et al.  Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. , 2001, Cancer research.

[16]  S. Croul,et al.  Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas , 2001, Oncogene.

[17]  J. Radich,et al.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. , 2001, Blood.

[18]  R. Baserga,et al.  IGF-I receptor signalling in transformation and differentiation , 2001, Molecular pathology : MP.

[19]  P. Lollini,et al.  Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  B. Chabner.  The oncologic four-minute mile. , 2001, The oncologist.

[21]  J. Karp,et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.

[22]  B. Druker,et al.  STI571: targeting BCR-ABL as therapy for CML. , 2001, The oncologist.

[23]  S. Kadereit,et al.  Protein kinase PKR is required for platelet‐derived growth factor signaling of c‐fos gene expression via Erks and Stat3 , 2001, The EMBO journal.

[24]  A. Doherty,et al.  Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. , 2001, Journal of medicinal chemistry.

[25]  J. McCubrey,et al.  Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. , 2001, Advances in enzyme regulation.

[26]  B. Druker,et al.  STI571: A gene product-targeted therapy for leukemia , 2001, Current oncology reports.

[27]  J. Rothberg,et al.  PDGF-D, a new protease-activated growth factor , 2001, Nature Cell Biology.

[28]  C. Geisler,et al.  Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells , 2001, Leukemia.

[29]  J. McCubrey,et al.  Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice , 2001, Leukemia.

[30]  J. McCubrey,et al.  Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells , 2001, Leukemia.

[31]  D. Morrison,et al.  KSR: a MAPK scaffold of the Ras pathway? , 2001, Journal of cell science.

[32]  U. Rapp,et al.  Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.

[33]  Hans van Dam,et al.  Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis , 2001, Oncogene.

[34]  M. Karin,et al.  AP-1 in cell proliferation and survival , 2001, Oncogene.

[35]  E. Wagner,et al.  AP-1 – Introductory remarks , 2001, Oncogene.

[36]  H. Sheng,et al.  Akt/PKB Activity Is Required for Ha-Ras-mediated Transformation of Intestinal Epithelial Cells* , 2001, The Journal of Biological Chemistry.

[37]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[38]  J. Martial,et al.  Inhibition of protein phosphatase PP1 in GH3B6, but not in GH3 cells, activates the MEK/ERK/c-fos pathway and the human prolactin promoter, involving the coactivator CPB/p300. , 2001, Molecular endocrinology.

[39]  Ulf R. Rapp,et al.  Apoptosis Suppression by Raf-1 and MEK1 Requires MEK- and Phosphatidylinositol 3-Kinase-Dependent Signals , 2001, Molecular and Cellular Biology.

[40]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[41]  M. Morgan,et al.  Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. , 2001, Blood.

[42]  S. Pelech,et al.  Stress-induced Inhibition of ERK1 and ERK2 by Direct Interaction with p38 MAP Kinase* , 2001, The Journal of Biological Chemistry.

[43]  HN Crans,et al.  Transcription factors and translocations in lymphoid and myeloid leukemia , 2001, Leukemia.

[44]  R. Baserga,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Limited Redundancy of Survival Signals from the Type 1 Insulin-Like Growth Factor Receptor* , 2022 .

[45]  J. Cleveland,et al.  The Max Network Gone Mad , 2001, Molecular and Cellular Biology.

[46]  G. Ehninger,et al.  Mutations in ras proto‐oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia , 2001, British journal of haematology.

[47]  C. Juhlin,et al.  Insulin-like growth factor-II in endocrine pancreatic tumours. Immunohistochemical, biochemical and in situ hybridization findings. , 2001, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[48]  P. Vogt,et al.  Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts , 2001, Oncogene.

[49]  M. Sadelain,et al.  Negative-Feedback Regulation of CD28 Costimulation by a Novel Mitogen-Activated Protein Kinase Phosphatase, MKP61 2 , 2001, The Journal of Immunology.

[50]  J. McCubrey,et al.  Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. , 2001, Cancer detection and prevention.

[51]  P. Ruvolo.  Ceramide regulates cellular homeostasis via diverse stress signaling pathways , 2001, Leukemia.

[52]  W. May,et al.  Phosphorylation of Bcl2 and regulation of apoptosis , 2001, Leukemia.

[53]  T. Fojo,et al.  The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy , 2001, Leukemia.

[54]  J. Sebolt-Leopold.  Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.

[55]  R. Muise-Helmericks,et al.  Signal transduction and the Ets family of transcription factors , 2000, Oncogene.

[56]  V. Sementchenko,et al.  Ets target genes: past, present and future , 2000, Oncogene.

[57]  S. Reffas,et al.  Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells. , 2000, The Biochemical journal.

[58]  J. McCubrey,et al.  The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. , 2000, Pharmacology & therapeutics.

[59]  J. McCubrey,et al.  Kinases: positive and negative regulators of apoptosis , 2000, Leukemia.

[60]  J. Argente,et al.  Modifications of growth velocity and the insulin-like growth factor system in children with acute lymphoblastic leukemia: a longitudinal study. , 2000, The Journal of clinical endocrinology and metabolism.

[61]  J. McCubrey,et al.  Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells , 2000, Leukemia.

[62]  Sandrine Perez,et al.  Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors , 2000, Oncogene.

[63]  D. Howard,et al.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.

[64]  T. Barber,et al.  Negative regulation of the serine/threonine kinase B-Raf by Akt. , 2000, The Journal of biological chemistry.

[65]  J. Roh,et al.  Transduction effect of antisense K-ras on malignant phenotypes in gastric cancer cells. , 2000, Cancer letters.

[66]  Shaomeng Wang,et al.  3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. , 2000, Journal of medicinal chemistry.

[67]  D. Morrison,et al.  Identification of B-KSR1, a Novel Brain-Specific Isoform of KSR1 That Functions in Neuronal Signaling , 2000, Molecular and Cellular Biology.

[68]  W. Kolch,et al.  Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation* , 2000, The Journal of Biological Chemistry.

[69]  S. Gammeltoft,et al.  A phosphoserine‐regulated docking site in the protein kinase RSK2 that recruits and activates PDK1 , 2000, The EMBO journal.

[70]  K. Tarte,et al.  JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen‐activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells , 2000, British journal of haematology.

[71]  J. McCubrey,et al.  Effects of deregulated RAF and MEK1 expression on the cytokine-dependency of hematopoietic cells. , 2000, Advances in enzyme regulation.

[72]  C. Kang,et al.  The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. , 2000, Leukemia research.

[73]  H. Nawata,et al.  Platelet-derived growth factor receptor tyrosine kinase inhibitor AG1295 attenuates rat hepatic stellate cell growth. , 2000, The Journal of laboratory and clinical medicine.

[74]  B. Rozell,et al.  Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[76]  C. Gélinas,et al.  The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-xL , 2000, Molecular and Cellular Biology.

[77]  S. Keyse,et al.  Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. , 2000, Current opinion in cell biology.

[78]  J. McCubrey,et al.  Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism , 2000, Leukemia.

[79]  J. McCubrey,et al.  Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias , 2000, Leukemia.

[80]  W. R. Bishop,et al.  A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. , 2000, Cancer research.

[81]  H. Enslen,et al.  Molecular determinants that mediate selective activation of p38 MAP kinase isoforms , 2000, The EMBO journal.

[82]  P. Crespo,et al.  Myeloid Leukemia Cell Growth and Differentiation Are Independent of Mitogen-activated Protein Kinase ERK1/2 Activation* , 2000, The Journal of Biological Chemistry.

[83]  F. Martin,et al.  MAP kinase pathway signalling is essential for extracellular matrix determined mammary epithelial cell survival , 2000, Cell Death and Differentiation.

[84]  J. Gutkind,et al.  Multiple Mitogen-Activated Protein Kinase Signaling Pathways Connect the Cot Oncoprotein to the c-junPromoter and to Cellular Transformation , 2000, Molecular and Cellular Biology.

[85]  J. McCubrey,et al.  A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells , 2000, Oncogene.

[86]  C. Herrmann,et al.  Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes , 2000, Oncogene.

[87]  D. Coppola,et al.  The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis , 2000, Molecular and Cellular Biology.

[88]  M. Camps,et al.  Dual specificity phosphatases: a gene family for control of MAP kinase function , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[89]  H Li,et al.  PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. , 2000, Nature cell biology.

[90]  C Gélinas,et al.  The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). , 2000, Molecular and cellular biology.

[91]  E. Goldsmith,et al.  Dimerization in MAP-kinase signaling. , 2000, Trends in biochemical sciences.

[92]  R. Eisenman,et al.  The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.

[93]  J. McCubrey,et al.  Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells , 2000, Leukemia.

[94]  J. McCubrey,et al.  Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells , 2000, Leukemia.

[95]  J. McCubrey,et al.  Serine/threonine phosphorylation in cytokine signal transduction , 2000, Leukemia.

[96]  E M Ross,et al.  GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. , 2000, Annual review of biochemistry.

[97]  L. Neckers,et al.  Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. , 2000, Blood.

[98]  T. Gonda,et al.  Myeloproliferative disorder and leukaemia in mice induced by different classes of constitutive mutants of the human IL-3/IL-5/GM-CSF receptor common β subunit , 1999, Oncogene.

[99]  D J Glass,et al.  Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. , 1999, Science.

[100]  K. Moelling,et al.  Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.

[101]  U. Rapp,et al.  Isotype-specific functions of Raf kinases. , 1999, Experimental cell research.

[102]  T. Sjöblom,et al.  Characterization of the chronic myelomonocytic leukemia associated TEL-PDGFβR fusion protein , 1999, Oncogene.

[103]  A. Ashworth,et al.  MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases , 1999, Oncogene.

[104]  G. Ghosh,et al.  Regulation of DNA binding by Rel/NF-κB transcription factors: structural views , 1999, Oncogene.

[105]  T. Gilmore,et al.  Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway , 1999, Oncogene.

[106]  Yoshiyuki Kuchino,et al.  Regulation of c-Myc through Phosphorylation at Ser-62 and Ser-71 by c-Jun N-Terminal Kinase* , 1999, The Journal of Biological Chemistry.

[107]  H. Ichijo,et al.  From receptors to stress-activated MAP kinases , 1999, Oncogene.

[108]  G. Prendergast,et al.  Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. , 1999, Cancer research.

[109]  P. Farnham,et al.  Identification of target genes of oncogenic transcription factors. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[110]  R. Jenison,et al.  A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX). , 1999, Combinatorial chemistry & high throughput screening.

[111]  B. Calabretta,et al.  Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis , 1999, Molecular and Cellular Biology.

[112]  K. Heidenreich,et al.  Insulin-like Growth Factor-I Induces bcl-2 Promoter through the Transcription Factor cAMP-Response Element-binding Protein* , 1999, The Journal of Biological Chemistry.

[113]  S. Gammeltoft,et al.  90-kDa Ribosomal S6 Kinase Is Phosphorylated and Activated by 3-Phosphoinositide-dependent Protein Kinase-1* , 1999, The Journal of Biological Chemistry.

[114]  P. Iversen,et al.  Simultaneous Antagonism of Interleukin-5, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-3 Stimulation of Human Eosinophils by Targetting the Common Cytokine Binding Site of Their Receptors , 1999 .

[115]  N. Ahn,et al.  Inhibition of Mitogen-Activated Kinase Signaling Sensitizes HeLa Cells to Fas Receptor-Mediated Apoptosis , 1999, Molecular and Cellular Biology.

[116]  J. Griffin,et al.  Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice. , 1999, Protein engineering.

[117]  D. Fabbro,et al.  The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. , 1999, Cancer research.

[118]  J. Smith,et al.  Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activated protein kinase family. , 1999, The Journal of biological chemistry.

[119]  C. Heldin,et al.  Functional co-operation between the subunits in heterodimeric platelet-derived growth factor receptor complexes. , 1999, The Biochemical journal.

[120]  Chris Albanese,et al.  NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1 , 1999, Molecular and Cellular Biology.

[121]  D. Brautigan,et al.  Protein phosphatase 2A suppresses MAP kinase signalling and ectopic protein expression. , 1999, Cellular signalling.

[122]  J. McCubrey,et al.  Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs , 1999, Leukemia.

[123]  E. Nishida,et al.  Molecular Cloning and Characterization of a Novel Dual Specificity Phosphatase, MKP-5* , 1999, The Journal of Biological Chemistry.

[124]  K. Schmiegelow,et al.  Insulin-like growth factor-I and insulin-like growth factor binding protein-3 during maintenance chemotherapy of acute lymphoblastic leukemia in children. , 1999, Journal of pediatric hematology/oncology.

[125]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[126]  C. Dunwiddie,et al.  Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. , 1999, Circulation.

[127]  L. Neckers,et al.  KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. , 1999, Cancer research.

[128]  W. Denny,et al.  Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. , 1999, Journal of medicinal chemistry.

[129]  A. Weiss,et al.  Induction of NF-κB by the Akt/PKB kinase , 1999, Current Biology.

[130]  J. Hahn,et al.  Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. , 1999, Blood.

[131]  X. P. Liu,et al.  Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[132]  J. Downward,et al.  Role of Phosphoinositide 3-Kinase in Activation of Ras and Mitogen-Activated Protein Kinase by Epidermal Growth Factor , 1999, Molecular and Cellular Biology.

[133]  Andrius Kazlauskas,et al.  PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1 , 1999, Current Biology.

[134]  Emmett V Schmidt,et al.  The role of c-myc in cellular growth control , 1999, Oncogene.

[135]  P. Vogt,et al.  Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[136]  J. Mestan,et al.  Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. , 1999, Pharmacology & therapeutics.

[137]  A. Beyerle,et al.  UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes. , 1999, The Journal of investigative dermatology.

[138]  N. Osheroff,et al.  Extracellular Signal-Regulated Kinase Activates Topoisomerase IIα through a Mechanism Independent of Phosphorylation , 1999, Molecular and Cellular Biology.

[139]  Giulio Superti‐Furga,et al.  Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation , 1999, The EMBO journal.

[140]  C. Mcwherter,et al.  Circular permutation of the granulocyte colony-stimulating factor receptor agonist domain of myelopoietin. , 1999, Biochemistry.

[141]  J. Griffin,et al.  Signaling Domains of the βc Chain of the GM‐CSF/IL‐3/IL‐5 Receptor , 1999 .

[142]  A. Ullrich,et al.  Epidermal growth factor receptors: critical mediators of multiple receptor pathways. , 1999, Current opinion in cell biology.

[143]  H. Saito,et al.  Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation , 1999, Leukemia.

[144]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[145]  B. Lutterbach,et al.  c‐Myc transactivation domain‐associated kinases: Questionable role for map kinases in c‐Myc phosphorylation , 1999, Journal of cellular biochemistry.

[146]  Y. Shounan,et al.  Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. , 1999, Blood.

[147]  J. Schlom,et al.  A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. , 1999, Journal of immunotherapy.

[148]  H. Moses,et al.  Inhibition of DNA Synthesis by a Farnesyltransferase Inhibitor Involves Inhibition of the p70s6k Pathway* , 1999, The Journal of Biological Chemistry.

[149]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[150]  J. Nevins,et al.  Ras enhances Myc protein stability. , 1999, Molecular cell.

[151]  K Kornfeld,et al.  Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. , 1999, Genes & development.

[152]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[153]  N. Bhat,et al.  Hydrogen Peroxide Activation of Multiple Mitogen‐Activated Protein Kinases in an Oligodendrocyte Cell Line , 1999, Journal of neurochemistry.

[154]  G. Rubin,et al.  Identification of Constitutive and Ras-Inducible Phosphorylation Sites of KSR: Implications for 14-3-3 Binding, Mitogen-Activated Protein Kinase Binding, and KSR Overexpression , 1999, Molecular and Cellular Biology.

[155]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[156]  飯田 美奈子.  Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation , 1999 .

[157]  H. Moses,et al.  Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway. , 1999, The Journal of biological chemistry.

[158]  F. E. Chen,et al.  Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. , 1999, Oncogene.

[159]  A. Weiss,et al.  Induction of NF-kappaB by the Akt/PKB kinase. , 1999, Current biology : CB.

[160]  R. Davis,et al.  Signal transduction by the c-Jun N-terminal kinase. , 1999, Biochemical Society symposium.

[161]  A. Wells.  EGF receptor. , 1999, The international journal of biochemistry & cell biology.

[162]  J. Abbruzzese,et al.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[163]  H. Pahl,et al.  Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.

[164]  S. Yokoyama,et al.  RNA aptamers that specifically bind to the Ras‐binding domain of Raf‐1 , 1998, FEBS letters.

[165]  P. Vogt,et al.  The akt kinase: molecular determinants of oncogenicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[166]  J. McCubrey,et al.  Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells , 1998, Leukemia.

[167]  C. Eaves,et al.  Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. , 1998, Blood.

[168]  M. Vadas,et al.  Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice. , 1998, The Journal of clinical investigation.

[169]  Kenneth M. Yamada,et al.  Tumor Suppressor PTEN Inhibits Integrin- and Growth Factor–mediated Mitogen-activated Protein (MAP) Kinase Signaling Pathways , 1998, The Journal of cell biology.

[170]  John Calvin Reed,et al.  Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.

[171]  M. Wigler,et al.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[172]  T. Taira,et al.  MM-1, a Novel c-Myc-associating Protein That Represses Transcriptional Activity of c-Myc* , 1998, The Journal of Biological Chemistry.

[173]  K. Nakamura,et al.  Beneficial effects of a novel inhibitor of platelet-derived growth factor receptor autophosphorylation in the rat with mesangial proliferative glomerulonephritis. , 1998, General pharmacology.

[174]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[175]  D. McConkey,et al.  CREB and Its Associated Proteins Act as Survival Factors for Human Melanoma Cells* , 1998, The Journal of Biological Chemistry.

[176]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[177]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[178]  C. Eaves,et al.  Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. , 1998, Blood.

[179]  F. Uckun,et al.  Role of Tyrosine Kinases in Induction of the c-junProto-oncogene in Irradiated B-lineage Lymphoid Cells* , 1998, The Journal of Biological Chemistry.

[180]  Jiahuai Han,et al.  The p38 MAP kinase pathway and its biological function. , 1998, Trends in cardiovascular medicine.

[181]  R. Copeland,et al.  Competitive inhibition of MAP kinase activation by a peptide representing the alpha C helix of ERK. , 1998, Biochemistry.

[182]  M. Marshall,et al.  In vitro inhibition of Ras-Raf association by short peptides. , 1998, Biochemical and biophysical research communications.

[183]  Phillip T. Hawkins,et al.  Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B , 1998, Current Biology.

[184]  B. Wasylyk,et al.  Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. , 1998, Trends in biochemical sciences.

[185]  L. M. Facchini,et al.  The molecular role of Myc in growth and transformation: recent discoveries lead to new insights , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[186]  S. Chevret,et al.  RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up , 1998, Leukemia.

[187]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[188]  M. Muda,et al.  Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. , 1998, Science.

[189]  E. Goldsmith,et al.  Phosphorylation of the MAP Kinase ERK2 Promotes Its Homodimerization and Nuclear Translocation , 1998, Cell.

[190]  A. Nordheim,et al.  Ets transcription factors and human disease. , 1998, Biochimica et biophysica acta.

[191]  J. Kornhauser,et al.  Nerve Growth Factor Activates Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Pathways To Stimulate CREB Serine 133 Phosphorylation , 1998, Molecular and Cellular Biology.

[192]  J. Blenis,et al.  pp90rsk1 Regulates Estrogen Receptor-Mediated Transcription through Phosphorylation of Ser-167 , 1998, Molecular and Cellular Biology.

[193]  J. McCubrey,et al.  Characterization of proteins binding the 3′ regulatory region of the IL-3 gene in IL-3-dependent and autocrine-transformed hematopoietic cells , 1998, Leukemia.

[194]  R. Klemke,et al.  Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis , 1998, The Journal of cell biology.

[195]  N. Ahn,et al.  Feedback Regulation of Raf-1 and Mitogen-activated Protein Kinase (MAP) Kinase Kinases 1 and 2 by MAP Kinase Phosphatase-1 (MKP-1)* , 1998, The Journal of Biological Chemistry.

[196]  J. Troppmair,et al.  Regulation of c-myc expression by Ras/Raf signalling , 1998, Oncogene.

[197]  J. Downward,et al.  Murine Ksr interacts with MEK and inhibits Ras-induced transformation , 1998, Current Biology.

[198]  S. Merchav.  The Haematopoietic Effects of Growth Hormone and Insulin-like Growth Factor-I , 1998, Journal of pediatric endocrinology & metabolism : JPEM.

[199]  A. Khwaja,et al.  A truncated isoform of the human beta chain common to the receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 with increased mRNA expression in some patients with acute leukemia. , 1998, Blood.

[200]  L. Wennogle,et al.  Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications. , 1998, Molecular pharmacology.

[201]  W. Fantl,et al.  Regulation of the MAP kinase pathway by mammalian Ksr through direct interaction with MEK and ERK , 1998, Current Biology.

[202]  V. Ramakrishnan,et al.  Functional Importance of Platelet-derived Growth Factor (PDGF) Receptor Extracellular Immunoglobulin-like Domains , 1997, The Journal of Biological Chemistry.

[203]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[204]  E. Nishida,et al.  A novel SAPK/JNK kinase, MKK7, stimulated by TNFα and cellular stresses , 1997, The EMBO journal.

[205]  A. Doherty,et al.  In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. , 1997, The Journal of pharmacology and experimental therapeutics.

[206]  Yong Jiang,et al.  Characterization of the Structure and Function of the Fourth Member of p38 Group Mitogen-activated Protein Kinases, p38δ* , 1997, The Journal of Biological Chemistry.

[207]  R Berger,et al.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.

[208]  L. Peso,et al.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. , 1997, Science.

[209]  J. Bos.  Ras-like GTPases. , 1997, Biochimica et biophysica acta.

[210]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[211]  J. McCubrey,et al.  Differential effects of retroviral long terminal repeats on interleukin-3 gene expression and autocrine transformation , 1997, Leukemia.

[212]  Colin B. Reese,et al.  3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase , 1997, Current Biology.

[213]  C. Heldin,et al.  Identification of a 190-kDa Vascular Endothelial Growth Factor 165 Cell Surface Binding Protein on a Human Glioma Cell Line* , 1997, The Journal of Biological Chemistry.

[214]  Elizabeth J. Goldsmith,et al.  Activation Mechanism of the MAP Kinase ERK2 by Dual Phosphorylation , 1997, Cell.

[215]  J A McCubrey,et al.  Autocrine transformation of human hematopoietic cells after transfection with an activated granulocyte/macrophage colony stimulating factor gene. , 1997, Cytokines, cellular & molecular therapy.

[216]  W. Greene,et al.  The 90-kDa Ribosomal S6 Kinase (pp90rsk) Phosphorylates the N-terminal Regulatory Domain of IκBα and Stimulates Its Degradation in Vitro * , 1997, The Journal of Biological Chemistry.

[217]  J. Brugge,et al.  Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation , 1997, Molecular and cellular biology.

[218]  A. Ullrich,et al.  Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[219]  A. Israël,et al.  IκBα is a target for the mitogen‐activated 90 kDa ribosomal S6 kinase , 1997 .

[220]  C. Heldin,et al.  Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. , 1997, Biochemistry.

[221]  C. Heldin,et al.  Immunoglobulin-like Domain 4-mediated Receptor-Receptor Interactions Contribute to Platelet-derived Growth Factor-induced Receptor Dimerization* , 1997, The Journal of Biological Chemistry.

[222]  J. McCubrey,et al.  Regulation of interleukin 3 expression in normal and autocrine transformed hematopoietic cells (Review). , 1997, International journal of oncology.

[223]  R. Kolesnick,et al.  Kinase Suppressor of Ras Is Ceramide-Activated Protein Kinase , 1997, Cell.

[224]  E. Anggard,et al.  Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. , 1997, Atherosclerosis.

[225]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[226]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[227]  B. Monia,et al.  Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. , 1997, Molecular pharmacology.

[228]  A. Ashworth,et al.  Molecular Cloning and Functional Characterization of a Novel Mitogen-activated Protein Kinase Phosphatase, MKP-4* , 1997, The Journal of Biological Chemistry.

[229]  C. Marshall,et al.  Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases* , 1997, The Journal of Biological Chemistry.

[230]  G. Evan,et al.  Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB , 1997, Nature.

[231]  David R. Kaplan,et al.  Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt , 1997, Science.

[232]  T. Maniatis,et al.  Activation of the IκBα Kinase Complex by MEKK1, a Kinase of the JNK Pathway , 1997, Cell.

[233]  J. Pouysségur,et al.  The Dual Specificity Mitogen-activated Protein Kinase Phosphatase-1 and −2 Are Induced by the p42/p44MAPK Cascade* , 1997, The Journal of Biological Chemistry.

[234]  T. Maniatis,et al.  Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. , 1997, Cell.

[235]  W. Greene,et al.  The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. , 1997, The Journal of biological chemistry.

[236]  A. Israël,et al.  IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. , 1997, The EMBO journal.

[237]  W. Kolch,et al.  PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. , 1996, Oncogene.

[238]  T. Golub,et al.  The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways , 1996 .

[239]  M. Abe,et al.  Ets‐1 regulates angiogenesis by inducing the expression of urokinase‐type plasminogen activator and matrix metalloproteinase‐1 and the migration of vascular endothelial cells , 1996, Journal of cellular physiology.

[240]  P. Cohen,et al.  Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.

[241]  N. Pathan,et al.  Activation of T Cell Raf-1 at Mitosis Requires the Protein-tyrosine Kinase Lck* , 1996, The Journal of Biological Chemistry.

[242]  M. Stella,et al.  Ets up-regulates MET transcription. , 1996, Oncogene.

[243]  A. Ashworth,et al.  The Dual Specificity Phosphatases M3/6 and MKP-3 Are Highly Selective for Inactivation of Distinct Mitogen-activated Protein Kinases* , 1996, The Journal of Biological Chemistry.

[244]  G. Rubin,et al.  KSR modulates signal propagation within the MAPK cascade. , 1996, Genes & development.

[245]  K. Xia,et al.  The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[246]  David Baltimore,et al.  NF-κB: Ten Years After , 1996, Cell.

[247]  L. Neckers,et al.  Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway , 1996, Molecular and cellular biology.

[248]  S. Fukumoto,et al.  The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclin-dependent kinase 2. , 1996, Circulation research.

[249]  H. Klocker,et al.  Androgen Receptor-Ets Protein Interaction Is a Novel Mechanism for Steroid Hormone-mediated Down-modulation of Matrix Metalloproteinase Expression* , 1996, The Journal of Biological Chemistry.

[250]  M. Farrar,et al.  Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization , 1996, Nature.

[251]  M. Polymenis,et al.  An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc , 1996, Molecular and cellular biology.

[252]  Michael E. Greenberg,et al.  Coupling of the RAS-MAPK Pathway to Gene Activation by RSK2, a Growth Factor-Regulated CREB Kinase , 1996, Science.

[253]  B. Spiegelman,et al.  Cellular transformation and malignancy induced by ras require c-jun , 1996, Molecular and cellular biology.

[254]  Wei Guo,et al.  Characterization of the Structure and Function of a New Mitogen-activated Protein Kinase (p38β)* , 1996, The Journal of Biological Chemistry.

[255]  M. Roussel,et al.  Inhibition of cell proliferation by the Mad1 transcriptional repressor , 1996, Molecular and cellular biology.

[256]  Michael C. Ostrowski,et al.  The transactivation potential of a c-Myc N-terminal region (residues 92-143) is regulated by growth factor/Ras signaling. , 1996, Nucleic acids research.

[257]  A. Ullrich,et al.  ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[258]  B. Hemmings,et al.  Role of protein phosphatase 2A in the regulation of mitogen-activated protein kinase activity in ventricular cardiomyocytes. , 1996, Biochemical and biophysical research communications.

[259]  J. Blenis,et al.  Phosphorylation of c-Fos at the C-terminus enhances its transforming activity. , 1996, Oncogene.

[260]  J. McCubrey,et al.  Malignant transformation induced by cytokine genes: a comparison of the abilities of germline and mutated interleukin 3 genes to transform hematopoietic cells by transcriptional and posttranscriptional mechanisms. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[261]  J. Blenis,et al.  Evidence for two catalytically active kinase domains in pp90rsk , 1996, Molecular and cellular biology.

[262]  J. McCubrey,et al.  Oncogenic effects of overexpression of the interleukin-3 receptor on hematopoietic cells. , 1996, Leukemia.

[263]  M. Muda,et al.  MKP-3, a Novel Cytosolic Protein-tyrosine Phosphatase That Exemplifies a New Class of Mitogen-activated Protein Kinase Phosphatase (*) , 1996, The Journal of Biological Chemistry.

[264]  A. Levitzki,et al.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.

[265]  R. Evans,et al.  Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism , 1996, Molecular and cellular biology.

[266]  Henry C. Chang,et al.  Protein phosphatase 2A positively and negatively regulates Ras1-mediated photoreceptor development in Drosophila. , 1996, Genes & development.

[267]  J. Ferrell,et al.  MAP kinases in mitogenesis and development. , 1996, Current topics in developmental biology.

[268]  D. Baltimore,et al.  NF-kappa B: ten years after. , 1996, Cell.

[269]  T. Golub,et al.  The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[270]  J. Gamble,et al.  Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist. , 1996, Blood.

[271]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[272]  A. Ashworth,et al.  Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54jnk. , 1995, Oncogene.

[273]  M. Cobb,et al.  Isolation of MEK5 and Differential Expression of Alternatively Spliced Forms * , 1995, The Journal of Biological Chemistry.

[274]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[275]  E M Schwarz,et al.  Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. , 1995, Genes & development.

[276]  Mikhail V. Blagosklonny,et al.  Disruption of the Raf-1-Hsp90 Molecular Complex Results in Destabilization of Raf-1 and Loss of Raf-1-Ras Association (*) , 1995, The Journal of Biological Chemistry.

[277]  H. Schaeffer,et al.  A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function , 1995, Molecular and cellular biology.

[278]  A. Bridges,et al.  A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[279]  E. Sausville,et al.  Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[280]  S. Weremowicz,et al.  RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: growth factor-stimulated kinase function and nuclear translocation , 1995, Molecular and cellular biology.

[281]  A. Saltiel,et al.  Inhibition of MAP Kinase Kinase Blocks the Differentiation of PC-12 Cells Induced by Nerve Growth Factor(*) , 1995, The Journal of Biological Chemistry.

[282]  E. Krebs,et al.  The MAPK signaling cascade , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[283]  A. Brunet,et al.  B-Raf protein isoforms interact with and phosphorylate Mek-1 on serine residues 218 and 222. , 1995, Oncogene.

[284]  Kun-Liang Guan,et al.  Isolation and Characterization of a Novel Dual Specific Phosphatase, HVH2, Which Selectively Dephosphorylates the Mitogen-activated Protein Kinase (*) , 1995, The Journal of Biological Chemistry.

[285]  N. Lydon,et al.  Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[286]  I. Dusanter-Fourt,et al.  Expression and activation of B-Raf kinase isoforms in human and murine leukemia cell lines. , 1995, Oncogene.

[287]  Jiahuai Han,et al.  Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms , 1995, Science.

[288]  S. Courtneidge,et al.  Src family protein tyrosine kinases and cellular signal transduction pathways. , 1995, Current opinion in cell biology.

[289]  L. Zon,et al.  Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun , 1994, Nature.

[290]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[291]  C. Heldin,et al.  Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. , 1994, Cancer research.

[292]  M. Karin,et al.  c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases , 1994, Molecular and cellular biology.

[293]  R. Takahashi,et al.  Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. , 1994, Journal of the National Cancer Institute.

[294]  G. Prendergast,et al.  c‐Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. , 1994, The EMBO journal.

[295]  H. Lee,et al.  Granulocyte-macrophage colony-stimulating factor and interleukin-3 signaling pathways converge on the CREB-binding site in the human egr-1 promoter , 1994, Molecular and cellular biology.

[296]  R. Hipskind,et al.  Transient activation of RAF-1, MEK, and ERK2 coincides kinetically with ternary complex factor phosphorylation and immediate-early gene promoter activity in vivo , 1994, Molecular and cellular biology.

[297]  E. Huberman,et al.  Differential induction of apoptosis in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[298]  N. Ahn,et al.  Transformation of mammalian cells by constitutively active MAP kinase kinase. , 1994, Science.

[299]  Ernst Hafen,et al.  The ETS domain protein Pointed-P2 is a target of MAP kinase in the Sevenless signal transduction pathway , 1994, Nature.

[300]  R. Hipskind,et al.  Ras/MAP kinase-dependent and -independent signaling pathways target distinct ternary complex factors. , 1994, Genes & development.

[301]  M. Greenberg,et al.  Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB , 1994, Cell.

[302]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[303]  E. Sausville,et al.  Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. , 1994, Molecular pharmacology.

[304]  H. Iba,et al.  Analysis of AP-1 function in cellular transformation pathways , 1994, Journal of virology.

[305]  K. Alitalo,et al.  Repression of cyclin D1: a novel function of MYC. , 1994, Molecular and cellular biology.

[306]  O. Silvennoinen,et al.  Signaling by the cytokine receptor superfamily: JAKs and STATs. , 1994, Trends in biochemical sciences.

[307]  J. Dodge,et al.  Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. , 1994, Cancer research.

[308]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[309]  M. Karin,et al.  JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain , 1994, Cell.

[310]  J. Darnell,et al.  Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions , 1994, Cell.

[311]  C. Zheng,et al.  Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues. , 1994, The EMBO journal.

[312]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[313]  D. Moller,et al.  Human rsk isoforms: cloning and characterization of tissue-specific expression. , 1994, The American journal of physiology.

[314]  Y. Satow,et al.  Platelet‐derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis , 1994, British journal of haematology.

[315]  R. Salgia,et al.  Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. , 1994, Experimental hematology.

[316]  R. Ross,et al.  Expression of platelet-derived growth factor and its receptors by two pre-B acute lymphocytic leukemia cell lines. , 1994, Blood.

[317]  C. N. Coleman,et al.  X-irradiation, phorbol esters, and H2O2 stimulate mitogen-activated protein kinase activity in NIH-3T3 cells through the formation of reactive oxygen intermediates. , 1994, Cancer research.

[318]  A. Arcaro,et al.  Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. , 1993, The Biochemical journal.

[319]  J. Blenis,et al.  Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[320]  K. Guan,et al.  Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. , 1993, The Journal of biological chemistry.

[321]  Hong Sun,et al.  MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo , 1993, Cell.

[322]  J. Rapp.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF , 1993 .

[323]  M. Karin,et al.  Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. , 1993, Genes & development.

[324]  Masatoshi Hagiwara,et al.  Phosphorylated CREB binds specifically to the nuclear protein CBP , 1993, Nature.

[325]  J. Sedivy,et al.  Raf-1 protein kinase activates the NF-kappa B transcription factor by dissociating the cytoplasmic NF-kappa B-I kappa B complex. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[326]  J. Brady,et al.  Transactivation of the P2 promoter of parathyroid hormone-related protein by human T-cell lymphotropic virus type I Tax1: evidence for the involvement of transcription factor Ets1 , 1993, Journal of virology.

[327]  J. Pouysségur,et al.  Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[328]  D. Morrison,et al.  Identification of the major phosphorylation sites of the Raf-1 kinase. , 1993, The Journal of biological chemistry.

[329]  J L Cleveland,et al.  The ornithine decarboxylase gene is a transcriptional target of c-Myc. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[330]  P. Warne,et al.  Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro , 1993, Nature.

[331]  S. Elledge,et al.  Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 , 1993, Nature.

[332]  Jonathan A. Cooper,et al.  Mammalian Ras interacts directly with the serine/threonine kinase raf , 1993, Cell.

[333]  Walter Kolch,et al.  Protein kinase Cα activates RAF-1 by direct phosphorylation , 1993, Nature.

[334]  M. Wigler,et al.  Complex formation between RAS and RAF and other protein kinases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[335]  S. Aaronson,et al.  Inhibition of platelet-derived growth factor autocrine growth stimulation by a monoclonal antibody to the human alpha platelet-derived growth factor receptor. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[336]  M. Weber,et al.  Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. , 1993, Science.

[337]  Julian Downward,et al.  Epidermal growth factor regulates p21 ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor , 1993, Cell.

[338]  E. Sausville,et al.  Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. , 1993, Cancer research.

[339]  U. Rapp,et al.  Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. , 1993, Toxicology letters.

[340]  J. Schlessinger,et al.  Specific phosphopeptide binding regulates a conformational change in the PI 3‐kinase SH2 domain associated with enzyme activation. , 1993, The EMBO journal.

[341]  V. Rotter,et al.  c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[342]  L. Donehower,et al.  Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. , 1993, Human gene therapy.

[343]  B. Wasylyk,et al.  The Ets family of transcription factors. , 1993, European journal of biochemistry.

[344]  W. Kolch,et al.  Protein kinase C alpha activates RAF-1 by direct phosphorylation. , 1993, Nature.

[345]  E. Krebs,et al.  Human T-cell mitogen-activated protein kinase kinases are related to yeast signal transduction kinases. , 1992, The Journal of biological chemistry.

[346]  R. Davis,et al.  Signal transduction within the nucleus by mitogen-activated protein kinase. , 1992, The Journal of biological chemistry.

[347]  M. Liyanage,et al.  Activation of the c-Raf protein kinase by protein kinase C phosphorylation. , 1992, Oncogene.

[348]  C. Crews,et al.  The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. , 1992, Science.

[349]  J. Ferrell,et al.  Inhibition of c-Jun DNA binding by mitogen-activated protein kinase. , 1992, Molecular biology of the cell.

[350]  T. Haystead,et al.  Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. , 1992, Science.

[351]  M. Chan,et al.  Genetic lesion in the carcinogenesis of cervical cancer. , 1992, Anticancer research.

[352]  S. Volinia,et al.  Phosphatidylinositol 3-kinase: Structure and expression of the 110 kd catalytic subunit , 1992, Cell.

[353]  K. Hartmann,et al.  Influence of antibodies against IGF-I, insulin or their receptors on proliferation of human acute lymphoblastic leukemia cell lines. , 1992, Leukemia research.

[354]  E. Nishida,et al.  Xenopus MAP kinase activator is a serine/threonine/tyrosine kinase activated by threonine phosphorylation. , 1992, The EMBO journal.

[355]  David L. Brautigan,et al.  Raf-1 activates MAP kinase-kinase , 1992, Nature.

[356]  W. Fantl,et al.  The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor beta receptor , 1992, Molecular and cellular biology.

[357]  G. Sonenshein,et al.  Transactivation of the c-myc gene by HTLV-1 tax is mediated by NFkB. , 1992, Current topics in microbiology and immunology.

[358]  R. Davis,et al.  A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression. , 1991, The Journal of biological chemistry.

[359]  M. Karin,et al.  Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73 , 1991, Nature.

[360]  J. McCubrey,et al.  Growth-promoting effects of insulin-like growth factor-1 (IGF-1) on hematopoietic cells: overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand-dependent mechanism , 1991 .

[361]  B. Wasylyk,et al.  Transformation suppressor activity of a Jun transcription factor lacking its activation domain , 1991, Nature.

[362]  Nancy Y. Ip,et al.  ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF , 1991, Cell.

[363]  M. Karin,et al.  Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain , 1991, Nature.

[364]  J. Shabanowitz,et al.  Identification of the regulatory phosphorylation sites in pp42/mitogen‐activated protein kinase (MAP kinase). , 1991, The EMBO journal.

[365]  J. Roth,et al.  Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. , 1991, Cancer research.

[366]  M. Pazin,et al.  A functional soluble extracellular region of the platelet-derived growth factor (PDGF) beta-receptor antagonizes PDGF-stimulated responses. , 1991, The Journal of biological chemistry.

[367]  T. Tamaoki.  Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors. , 1991, Methods in enzymology.

[368]  Y. Dudai,et al.  The structure of protein phosphatase 2A is as highly conserved as that of protein phosphatase I , 1990, FEBS letters.

[369]  N. Langeland,et al.  A monoclonal antibody against PDGF B-chain inhibits PDGF-induced DNA synthesis in C3H fibroblasts and prevents binding of PDGF to its receptor. , 1990, Biochimica et biophysica acta.

[370]  C. Slaughter,et al.  An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. , 1990, Science.

[371]  H. Häring,et al.  An altered IGF-I receptor is present in human leukemic cells. , 1990, The Journal of biological chemistry.

[372]  P. Baeuerle,et al.  NF-kappa B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene , 1990, Molecular and cellular biology.

[373]  D. Alcorta,et al.  Sequence and expression of chicken and mouse rsk: homologs of Xenopus laevis ribosomal S6 kinase , 1989, Molecular and cellular biology.

[374]  T. Sturgill,et al.  Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[375]  D. Fabbro,et al.  A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity , 1989, International journal of cancer.

[376]  J. Minna,et al.  Loss of heterozygosity at the c-raf locus in small cell lung carcinoma. , 1989, Oncogene.

[377]  T. Haystead,et al.  Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism , 1989, Nature.

[378]  J. Maller,et al.  Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II , 1988, Nature.

[379]  D. McClain,et al.  Effects of insulin and insulin-like growth factor I on growth of human leukemia cells in serum-free and protein-free medium. , 1988, Blood.

[380]  Felix Franks,et al.  Characterization of Proteins , 1988, Humana Press.

[381]  L. Cantley,et al.  Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate , 1988, Nature.

[382]  I. Takahashi,et al.  UCN-01, a selective inhibitor of protein kinase C from Streptomyces. , 1987, The Journal of antibiotics.

[383]  T. Sugimura,et al.  Rat c-raf oncogene activation by a rearrangement that produces a fused protein , 1987, Molecular and cellular biology.

[384]  R. Tjian,et al.  Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40 , 1987, Nature.

[385]  G. Evan,et al.  The protein encoded by the human proto-oncogene c-myc. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[386]  C. Croce,et al.  Identification of the c-myc oncogene product in normal and malignant B cells. , 1983, Science.